VIA Pops on Subset Analysis from Phase II ACS Trial
Shares of VIA Pharmaceuticals Inc. jumped 50 percent in midday trading Friday after the company presented a subset analysis from its Phase II trial of VIA-2291 in acute coronary syndrome. The trial previously met its primary endpoint of significantly inhibiting Leukotriene B4 production. The subset [...]